Shareholding for the Period Ended June 30, 2016
Sun Pharmaceutical Industries Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2016. For more details, kindly Click here22-07-2016
22-07-2016
Sun Pharma gets FDA nod for rosuvastatin calcium tablets
Drug major Sun Pharma has received final approval from the US health regulator USFDA for rosuvastatin calcium tablets, used in lowering cholesterol.In a BSE filing, Sun Pharma said: One of its subsi...20-07-2016
Sun Pharma announces US FDA approval for generic Crestor
Sun Pharmaceutical Industries Ltd has informed BSE regarding a Press Release dated July 20, 2016 titled "Sun Pharma announces US FDA approval for generic Crestor".20-07-2016
Buy Sun Pharmaceutical Industries, target Rs 794: Microsec Capital
Buy Sun Pharmaceutical Industries Ltd. at a price target of Rs 794 and a stop loss at Rs 76019-07-2016
Sun Pharma partners SPARC to market epilepsy drug in US
SPARC will give the licence of Elepsia XRTM to a Sun Pharma subsidiary for the US market and will receive an upfront payment of $10 million for it18-07-2016
SPARC Licenses ELEPSIA XR(Levetiracetam ER Tablets) to Sun Pharma
Sun Pharmaceutical Industries Ltd has informed BSE regarding a Press Release dated July 18, 2016 titled "SPARC Licenses ELEPSIA XR(Levetiracetam ER Tablets) to Sun Pharma".18-07-2016
Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended June 30, 2016
Sun Pharmaceutical Industries Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended June 30, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.14-07-2016
Sun Pharma brings back old hand Kalyanasundaram Subramanian from Taro Pharmaceutical Industries
The decision to bring back Sundaram from Taro signals a move that's possibly aimed at shaping the next stage of growth for India's largest drugmaker, experts said.13-07-2016
Sun Pharmas Leadership update for India, North America and Emerging Markets
Sun Pharmaceutical Industries Ltd has informed BSE about "Sun Pharmas Leadership update for India, North America and Emerging Markets".13-07-2016
Sun Pharma starts rollout of Gemcitabine InfuSMART in six European nations
Gemcitabine is indicated in the treatment of ovarian, lung, breast and pancreatic cancer. Sun Pharma hinted at more oncology products being developed on the same lines.11-07-2016